Evidence map›Paper›PMID 42819414›Full record

ArticleMedComm2026

Presenilin 1 Mutations Converge on Aβ42/Aβ40 Elevation via Distinct Mechanisms.

Isabel Bestard-Lorigados, Keenan Sterling, Liwei Li, Zhehao Lin, Zhanghui Wu, Qinxin Zhu, Wenhao Pan, Fang Cai, Weihong Song

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Isabel Bestard-LorigadosDepartment of Psychiatry Townsend Family Laboratories Graduate Program in Neuroscience The University of British Columbia Vancouver Canada.
Keenan SterlingDepartment of Psychiatry Townsend Family Laboratories Graduate Program in Neuroscience The University of British Columbia Vancouver Canada.
Liwei LiCenter For Geriatric Medicine Zhejiang Key Laboratory of Alzheimer's Disease and Institute of Aging The First Affiliated Hospital of Wenzhou Medical University Wenzhou China.
Zhehao LinCenter For Geriatric Medicine Zhejiang Key Laboratory of Alzheimer's Disease and Institute of Aging The First Affiliated Hospital of Wenzhou Medical University Wenzhou China.
Zhanghui WuCenter For Geriatric Medicine Zhejiang Key Laboratory of Alzheimer's Disease and Institute of Aging The First Affiliated Hospital of Wenzhou Medical University Wenzhou China.
Qinxin ZhuCenter For Geriatric Medicine Zhejiang Key Laboratory of Alzheimer's Disease and Institute of Aging The First Affiliated Hospital of Wenzhou Medical University Wenzhou China.
Wenhao PanCenter For Geriatric Medicine Zhejiang Key Laboratory of Alzheimer's Disease and Institute of Aging The First Affiliated Hospital of Wenzhou Medical University Wenzhou China.
Fang CaiOujiang Laboratory (Zhejiang Lab For Regenerative Medicine, Vision and Brain Health) Wenzhou China.
Weihong SongDepartment of Psychiatry Townsend Family Laboratories Graduate Program in Neuroscience The University of British Columbia Vancouver Canada.ORCID https://orcid.org/0000-0001-9928-889X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in Presenilin 1 (PS1) are the most common genetic cause of familial Alzheimer's disease (AD). However, the exact mechanisms by which these mutations alter amyloid precursor protein (APP) processing and drive amyloid β (Aβ) production remain unclear. In this study, five PS1 mutations (M146V, G384A, C410Y, Y115H, and the Notch-sparing mutation ΔS169) were transfected into neuroblastoma cells lacking endogenous PS1/PS2 expression and human embryonic kidney cells stably overexpressing either wild-type APP or the APP Swedish mutation. We investigated the effects of these mutations on APP processing, Aβ42/Aβ40 ratio, cytotoxicity, BACE1 expression, and PS1 endoproteolysis. Our results demonstrate that PS1 mutations differentially modulate APP processing, producing distinct Aβ profiles independent of their effects on Notch signaling. All mutations increased the Aβ42/Aβ40 ratio, while BACE1 levels were unchanged and no direct PS1-BACE1 interactions were found. All mutations increased cytotoxicity, whereas only the Notch-impairing mutations reduced cell viability, suggesting impaired Notch signaling may contribute to this effect. Lastly, the mutations exhibited distinct endoproteolytic rates that correlated only with APP-C83 levels. These findings provide novel insights into how distinct PS1 mutations impact amyloid pathology.

Indexed as

Alzheimer's diseaseamyloid β peptidesBACE1endoproteolysispresenilin 1

Identifiers

PMID42819414
PMCPMC13625817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.